Join to view full profile
40 Duke Medicine CirDurham, NC 27710
Phone+1 919-684-8111
Dr. Vlahovic is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 2000 - 2003- Duke University HospitalResidency, Internal Medicine, 1997 - 2000
University of Zagreb Faculty of MedicineClass of 1987
Certifications & Licensure
NC State Medical License 2001 - 2022
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
Clinical Trials
- Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer
- Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia Start of enrollment: 2007 Apr 24
- Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Start of enrollment: 2006 Feb 06
Publications & Presentations
PubMed
- 13 citationsA peptide vaccine targeting the CMV antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma: a phase 1 trial.Eric M Thompson, David M Ashley, Katayoun Ayasoufi, Pamela Norberg, Gerald Archer
Nature Cancer. 2025-09-01 - 582 citationsDurvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial.Eileen M. O'Reilly, Do Youn Oh, Neesha C. Dhani, Daniel J. Renouf, Myung Ah Lee
JAMA Oncology. 2019-10-01 - 21 citationsTolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors.Yutaka Fujiwara, Haruo Iguchi, Noboru Yamamoto, Manabu Hayama, Masahiro Nii
Cancer Science. 2019-05-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: